Structural modification of a non-selective aminocyclohexanol-based heat shock protein 90 KDa (Hsp90) inhibitor led to a highly selective inhibitor of glucose regulated protein 94 kDa (Grp94). The new Grp94-selective inhibitor can be used to develop an effective therapy for the treatment of metastatic cancer and/or primary open angle glaucoma (POAG).
This novel process uses atomic layer deposition (ALD) to grow a tunnel barrier one atomic layer at a time. Placed between two electrically conducting materials, a tunnel barrier forms a tunnel junction. Electrons pass through the barrier by quantum tunneling. This process forms more uniform, thinner, and lower defect tunnel barriers. By improving the likelihood of quantum tunneling, this process creates higher performing tunnel junction devices.
A low-cost telemedicine tool featuring a virtual reality (VR) interface has been designed and developed to assist with the evaluation and diagnosis of neurodegenerative disease, thereby enabling greater access to care and earlier diagnosis for patients with neurological disorders; even for those in remote areas, or with limited transportation options.
Use of a genetic dereplication strategy eliminates major known SM biosynthetic pathways in Aspergillus nidulans, reducing the complexity of SM profiles and activating an abundance of silent SM gene clusters to enable identification of a new pool of fungal products for drug discovery.
The small molecules in this work represent a novel composition of matter that can be used as either Kappa Opioid Receptor (KOR) agonists or antagonists. Further some of the compounds have been shown to weak agonists making them ideal to explore for the use of addiction.